Positive psychology program for older adults with early memory and thinking decline
Tests an online positive psychology program in older adults with early cognitive decline.
Plain-language title generated from the registry record
Registry title: Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function
Key facts
- Where
- Thessaloniki, GreeceSee the site
Where in Greece
- Aristotle University of ThessalonikiThessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aristotle University Of Thessaloniki
- Trial code
- NCT07289061
- Record updated
- 7 January 2026
- Original description
This randomized study tests whether a new multicomponent Positive Psychology program can improve cognition and wellbeing in older adults at the earliest stages of dementia-related decline.Read full original descriptionShow less
Application of Positive Psychology Interventions in Individuals With Early-stage Cognitive Decline Related to Dementia: Their Impact on Cognitive and Brain Functioning
This randomized study tests whether a new multicomponent Positive Psychology program can improve cognition and wellbeing in older adults at the earliest stages of dementia-related decline.
About 128 participants with Subjective Cognitive Decline or Mild Cognitive Impairment will be enrolled. Half will be randomized to the Positive Psychology program and half to Treatment As Usual (TAU).
The program consists of weekly, small-group online sessions for ~24 weeks plus brief home practices. All participants (both arms) will complete questionnaires and cognitive tests at baseline, during treatment, post-treatment, and 9-month follow-up.
Primary question: Do participants receiving the Positive Psychology program show better cognitive and brain-function outcomes than TAU at post-treatment and at 9 months? Secondary question: Are effects larger for SCD than MCI? No medicines are used and risks are minimal. If effective, this scalable, low-cost, non-pharmacological approach could complement usual care for people in very early cognitive decline.
Inclusion: -Documented diagnosis of Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) according to clinical evaluation and site standard criteria.
Exclusion: Concurrent participation in another interventional study targeting cognition or wellbeing during the study period; Diagnosis of dementia (major neurocognitive disorder) or other major neurocognitive disorder that is moderate or severe; Major psychiatric disorder currently unstable or untreated (e.g., major depression with psychotic features, bipolar disorder, schizophrenia); Neurological conditions that affect cognition; Uncorrected hearing or vision problems that prevent participation in assessments or online sessions.